Tang Y.-D.,Jiangsu Engineering Research Center for Biomedical Function Materials |
Tang Y.-D.,Nanjing Normal University |
Zhou N.-L.,Jiangsu Engineering Research Center for Biomedical Function Materials |
Zhou N.-L.,Nanjing Normal University |
And 9 more authors.
Gaodeng Xuexiao Huaxue Xuebao/Chemical Journal of Chinese Universities | Year: 2012
Carboxyl modifiedgraphene oxide is important in the preparation of functionalized graphene oxide(GeneO). In this work, the free radical initiator agent azobisisobutyronitrile(AIBN) was functioned as a modifier. AIBN could be separated into isobutyronitrile radicals to attack the five-membered ring and seven-membered ring defects in the graphene oxide. Then the cyanogroup-modified graphene oxide intermediates were formed, and the carboxyl graphene oxide[GeneO-C(CH3)2-COOH] could be obtained through the hydrolysis reaction. The structure and properties of GeneO-C(CH3)2-COOH were characterized by Fourier transform infrared spectroscope(FTIR), X-ray diffraction(XRD), thermo gravimetric analyzer(TGA) and atomic force microscope(AFM). And the blood compatibility of GeneO-C(CH3)2-COOH was evaluated by recalcification time test. It was showed that the recalcification time gradually decreased as the increasing concentration of GeneO-C(CH3)2-COOH, indicating that the material had good blood compatibility. Carboxyl group content could be controlled by the mass ratio of AIBN to GeneO. This method not only could increase the carboxyl content of oxidized graphene, but also made the material have a good blood compatibility. Source
Tan J.,Nanjing Normal University |
Tan J.,Jiangsu Engineering Research Center for Biomedical Function Materials |
Meng N.,Nanjing Normal University |
Meng N.,Jiangsu Engineering Research Center for Biomedical Function Materials |
And 11 more authors.
Materials Science and Engineering C | Year: 2016
A novel drug carrier based on hydroxypropyl-β-cyclodextrin (HP-β-CD) modified carboxylated graphene oxide (GO-COOH) was designed to incorporate anti-cancer drug paclitaxel (PTX). The formulated nanomedicines were characterized by Fourier transform infrared spectroscopy (FTIR) and atomic force microscopy (AFM). Results showed that PTX can be incorporated into GO-COO-HP-β-CD nanospheres successfully, with an average diameter of about 100 nm. The solubility and stability of PTX-loaded GO-COO-HP-β-CD nanospheres in aqueous media were greatly enhanced compared with the untreated PTX. The results of hemolysis test demonstrated that the drug-loaded nanospheres were qualified with good blood compatibility for intravenous use. In vitro anti-tumor activity was measured and results demonstrated that the incorporation of PTX into the newly developed GO-COO-HP-β-CD carrier could confer significantly improved cytotoxicity to the nanosystem against tumor cells than single application of PTX. GO-COO-HP-β-CD nanospheres may represent a promising formulation platform for a broad range of therapeutic agent, especially those with poor solubility. © 2016 Elsevier B.V. All rights reserved. Source